Trial Profile
A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Effects of Repeated Subcutaneous Doses of E1 in Combination With G1 in Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Epidermal growth factor (Primary) ; TT 223 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors OPKO Health; Transition Therapeutics
- 05 Mar 2007 Interim results have been published (at 3-months post-treatment)
- 27 Jun 2006 New trial record.